pheneticillin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, 6-aminopenicillanic acid derivatives 2124 147-55-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • phenethicillin potassium
  • pheneticillin
  • feneticillin
  • phenethicillin
  • phenoxyethylpenicillin
  • alfacilin
  • phenethicillin potassium salt
pheneticillin (feneticillin) is an oral acid resistant penicillin analogous to penicillin V with a range of antimicrob activity similar to penicillin G
  • Molecular weight: 364.42
  • Formula: C17H20N2O5S
  • CLOGP: 2.25
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 95.94
  • ALOGS: -3.01
  • ROTB: 5

Drug dosage:

DoseUnitRoute
1 g O

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.25 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.91 hours Lombardo F, Berellini G, Obach RS
BA (Bioavailability) 86 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.904 Moderate 0.69
caco2-efflux Caco-2 efflux ratio (BA/AB) 2.773 Moderate 0.69
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.818 10^-6 cm/s Moderate 0.69
dh-clint Dog hepatocyte intrinsic clearance 3.597 uL/min/10^6 cells Moderate 0.69
dppb Dog plasma protein binding (% unbound) 55.280 % Moderate 0.69
fcs-ppb Fetal calf serum protein binding (% unbound) 42.180 % Moderate 0.69
herg hERG pIC50 4.386 pIC50 Moderate 0.69
hh-clint Human hepatocyte intrinsic clearance 1.600 uL/min/10^6 cells Moderate 0.69
hlm-clint Human liver microsomal intrinsic clearance 3.155 uL/min/mg protein Moderate 0.69
hppb Human plasma protein binding (% unbound) 52.880 % Moderate 0.69
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PIM2,PRKDC,STK33,SYK,TEK,TGFBR1,ZAP70 37
kinase-selectivity-class AXL,GRK2,MAP2K6 3
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.804 Moderate 0.68
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.955 Moderate 0.69
mh-clint Mouse hepatocyte intrinsic clearance 8.279 Moderate 0.69
mppb Mouse plasma protein binding (% unbound) 47.070 Moderate 0.69
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.735 Moderate 0.69
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 35.310 % Moderate 0.69
rat-kpuu-brain Rat brain Kpuu 0.009 % Moderate 0.68
rh-clint Rat hepatocyte intrinsic clearance 4.592 uL/min/10^6 cells Moderate 0.69
rh-fuinc Rat hepatocyte fraction unbound in incubation 83.680 % Moderate 0.69
rppb Rat plasma protein binding (% unbound) 42.520 % Moderate 0.69
solubility-dd Solubility at pH 7.4 in DMSO 933.254 uM Moderate 0.69

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic reaction 197.60 104.00 37 50 87487 90540873
Drug intolerance 142.44 104.00 38 49 447553 90180807

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic reaction 197.88 84.07 38 56 114262 110474943
Drug intolerance 144.62 84.07 37 57 406475 110182730

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Plagiocephaly 17.70 7.19 3 3 75 113872

Pharmacologic Action:

SourceCodeDescription
ATC J01CE05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Beta-lactamase sensitive penicillins
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:33282 antibacterial agent

Related Drugs by ATC class:

J01CE Beta-lactamase sensitive penicillins 9 drugs
azidocillinbenzathine benzylpenicillinbenzathine phenoxymethylpenicillinbenzylpenicillinclometocillinpenamecillinphenoxymethylpenicillinprocaine benzylpenicillinpropicillin

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.79 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D01178 KEGG_DRUG
132-93-4 SECONDARY_CAS_RN
CHEBI:52427 CHEBI
CHEMBL1614637 ChEMBL_ID
CHEMBL2364720 ChEMBL_ID
12275 IUPHAR_LIGAND_ID
1011 INN_ID
DB13337 DRUGBANK_ID
EFA30X554H UNII
132907 RXNORM
002687 NDDF
004958 NDDF
14706000 SNOMEDCT_US
387084009 SNOMEDCT_US
C0070557 UMLSCUI
272833 PUBCHEM_CID
C113778 MESH_SUPPLEMENTAL_RECORD_UI
C100209 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

None